Company / PP&E per Share
MoonLake Immunotherapeutics PP&E per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$0.01
FY2025
5-year range
$0.00 / $0.01
FY2021-FY2025
Trend
-22.1%
vs FY2024
Sector context
#164 of 191
Health Care
What the data says
MoonLake Immunotherapeutics's pp&e per share of $0.01 is lower than 86% of companies in the Health Care sector (FY2025). Improved from $0.01 to $0.01 over the past 2 years.
Based on SEC 10-K filings.
0.01 in FY2025 with a 3-year CAGR of +74.6%.
Improved from $0.01 to $0.01 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- +74.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 191This company $0.01 Sector average $22.34
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, pp&e per share decreased 22.1% year-over-year.
- Ranks #164 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2024.
- Lowest pp&e per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -22.1% |
| FY2024 | $0.01 | +75.8% |
| FY2023 | $0.01 | +288.3% |
| FY2022 | $0.00 | -71.2% |
| FY2021 | $0.01 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026